NO20003246L - New pharmaceutical preparations of uridine triphosphate - Google Patents

New pharmaceutical preparations of uridine triphosphate

Info

Publication number
NO20003246L
NO20003246L NO20003246A NO20003246A NO20003246L NO 20003246 L NO20003246 L NO 20003246L NO 20003246 A NO20003246 A NO 20003246A NO 20003246 A NO20003246 A NO 20003246A NO 20003246 L NO20003246 L NO 20003246L
Authority
NO
Norway
Prior art keywords
utp
formulation
new
pharmaceutical preparations
aqueous solution
Prior art date
Application number
NO20003246A
Other languages
Norwegian (no)
Other versions
NO20003246D0 (en
Inventor
Karol K Lacroix
Christy L Shaffer
Karla M Jacobus
Janet L Rideout
David J Drutz
Richard M Evans
William Pendergast
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Publication of NO20003246D0 publication Critical patent/NO20003246D0/en
Publication of NO20003246L publication Critical patent/NO20003246L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Nye farmasøytiske preparater av uridin-5'-trifosfat (UTP) til bruk for å fremme økt mukociliær renselse av bibeholdte mukøse sekresjoner i luftveiene, mellomøret/det indre øret eller sinusene hos mennesker. Den nye formulering (I) omfatter UTP og vandig oppløsning som har en terapeutisk konsentrasjon mellom 5 og 45 mg/ml, en regulert tonisitet innen området 250 til 100 mOsM, en pH mellom 7,0 og 7,5, og er steril. Det pH-justerte preparat kan lagres i lang tid i nedkjølt tilstand med en lagringsbestandighet opp til 30 måneder. Formulering (I) kan tilføres terapeutisk enten i en forstøvet form eller i en flytende form. Den nye formulering (II) omfatter UTP i en vandig oppløsning som har en tera- peutisk konsentrasjon som nærmer seg solubilitetsgrensen til UTP ved omgivelsestemperatur eller i en suspensjon som overstiger solubiliteten av medikament. Denne høye konsentrasjonen tillater tilførsel av en terapeutisk mengde av UTP i svært små volumer (50 til 100 fj.1) som er egnet for administrering via bærbare håndholdte innretninger slik som inhalatorer med utmålt dose. Formulering (II) har forlenget lagringsbestandighet uten behov for nedkjøling etter tildeling til pasienten.New pharmaceutical preparations of uridine 5'-triphosphate (UTP) for use in promoting increased mucociliary clearance of retained mucosal secretions in the respiratory tract, middle ear, or inner ear or the sinuses of humans. The new formulation (I) comprises UTP and aqueous solution having a therapeutic concentration between 5 and 45 mg / ml, a controlled tonicity in the range of 250 to 100 mOsM, a pH between 7.0 and 7.5, and is sterile. The pH-adjusted preparation can be stored for a long time in the refrigerated state with a storage resistance up to 30 months. Formulation (I) can be applied therapeutically either in a nebulized form or in a liquid form. The new formulation (II) comprises UTP in an aqueous solution having a therapeutic concentration approaching the solubility limit of UTP at ambient temperature or in a suspension exceeding the solubility of drug. This high concentration allows the administration of a therapeutic amount of UTP in very small volumes (50 to 100 µl) suitable for administration via portable handheld devices such as metered dose inhalers. Formulation (II) has prolonged storage resistance without the need for refrigeration upon assignment to the patient.

NO20003246A 1997-12-23 2000-06-21 New pharmaceutical preparations of uridine triphosphate NO20003246L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/996,740 US5968913A (en) 1996-07-03 1997-12-23 Pharmaceutical compositions of uridine triphosphate
PCT/US1998/027409 WO1999032085A2 (en) 1997-12-23 1998-12-23 Novel pharmaceutical compositions of uridine triphosphate

Publications (2)

Publication Number Publication Date
NO20003246D0 NO20003246D0 (en) 2000-06-21
NO20003246L true NO20003246L (en) 2000-08-23

Family

ID=25543248

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003246A NO20003246L (en) 1997-12-23 2000-06-21 New pharmaceutical preparations of uridine triphosphate

Country Status (17)

Country Link
US (1) US5968913A (en)
EP (1) EP1041969B1 (en)
JP (1) JP2001526208A (en)
KR (1) KR20010033310A (en)
CN (1) CN1143672C (en)
AR (1) AR014176A1 (en)
AT (1) ATE235225T1 (en)
AU (1) AU747350B2 (en)
BR (1) BR9814426A (en)
CA (1) CA2316018A1 (en)
DE (1) DE69812708T2 (en)
ID (1) ID26137A (en)
IL (1) IL136895A0 (en)
NO (1) NO20003246L (en)
NZ (1) NZ505821A (en)
WO (1) WO1999032085A2 (en)
ZA (1) ZA9811833B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
TW593331B (en) 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
WO1999005155A2 (en) 1997-07-25 1999-02-04 Inspire Pharmaceuticals, Inc. Salts of di(uridine 5'-tetraphosphate), method for preparation and uses thereof
US6872710B2 (en) * 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US6327215B1 (en) * 2000-09-28 2001-12-04 Vanguard International Semiconductor Corporation Local bit switch decode circuit and method
JP2005508297A (en) 2001-06-25 2005-03-31 インスパイアー ファーマシューティカルズ，インコーポレイティド Joint lubrication by P2Y purine receptor agonist
JP2005532254A (en) * 2001-11-06 2005-10-27 インスパイアー ファーマシューティカルズ，インコーポレイティド Method for treating or preventing inflammatory diseases
JP2006505585A (en) * 2002-10-18 2006-02-16 モリケム メディシンズ， インコーポレイテッド How to treat dry eye with lantibiotics
EP1753445A4 (en) * 2004-05-06 2009-05-20 Molichem Medicines Inc Treatment of ocular diseases and disorders using lantibiotic compositions
WO2005107787A1 (en) * 2004-05-06 2005-11-17 Molichem Medicines, Inc. Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
US7368439B2 (en) * 2005-06-15 2008-05-06 Bar - Ilan University Dinucleoside poly(borano)phosphate derivatives and uses thereof
US20120077778A1 (en) * 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
EP2556832B1 (en) 2011-08-12 2017-07-19 Universitätsklinikum Freiburg Uridine and uridine analogues for use in the treatment of chronic obstructive pulmonary disease
US9034442B2 (en) * 2012-11-30 2015-05-19 Corning Incorporated Strengthened borosilicate glass containers with improved damage tolerance
US10117806B2 (en) * 2012-11-30 2018-11-06 Corning Incorporated Strengthened glass containers resistant to delamination and damage

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB916309A (en) * 1959-12-14 1963-01-23 Ile Auguil Soc Civ Improvements in and relating to new therapeutic preparation for use as a muscular and nervous stimulant
JPS60126220A (en) * 1983-12-09 1985-07-05 Otsuka Pharmaceut Factory Inc Nucleic acid component composition
GB9027968D0 (en) * 1990-12-22 1991-02-13 Fisons Plc Method of treatment
US5164740A (en) * 1991-04-24 1992-11-17 Yehuda Ivri High frequency printing mechanism
FR2677250B1 (en) * 1991-06-05 1995-01-20 Synthelabo PHARMACEUTICAL COMPOSITIONS CONTAINING DISOD ADENOSINE-5-TRIPHOSPHATE.
EP0517573A1 (en) * 1991-06-05 1992-12-09 Synthelabo Pharmaceutical compositions for the treatment of airway disorders
US5292498A (en) * 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
ATE131421T1 (en) * 1991-12-04 1995-12-15 The Technology Partnership Plc DEVICE AND METHOD FOR GENERATING LIQUID DROPS
US5547131A (en) * 1992-12-04 1996-08-20 Bespak Plc Dispensing device with spray nozzle and driven piston
US5497763A (en) * 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5593824A (en) * 1994-09-02 1997-01-14 Pharmacia Biotech, Inc. Biological reagent spheres
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
US6423694B1 (en) * 1996-02-21 2002-07-23 Inspire Pharmaceuticals, Inc. Method of treating otitis media with uridine triphosphates and related compounds
EP0889728B1 (en) * 1996-03-27 2006-08-09 Inspire Pharmaceuticals, Inc. Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
US5962432A (en) * 1996-07-03 1999-10-05 Inspire Pharmaceuticals, Inc. Sterilized, isotonic and pH-adjusted pharmaceutical formulation of uridine triphosphate
US5789391A (en) * 1996-07-03 1998-08-04 Inspire Pharmaceuticals, Inc. Method of treating sinusitis with uridine triphosphates and related compounds
US5763447C1 (en) * 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US6159952A (en) * 1996-11-07 2000-12-12 Inspire Pharmaceuticals, Inc. Method of treating bronchitis with uridine triphosphate and related compounds

Also Published As

Publication number Publication date
NZ505821A (en) 2002-09-27
WO1999032085A3 (en) 1999-09-02
ATE235225T1 (en) 2003-04-15
AU2092299A (en) 1999-07-12
CN1143672C (en) 2004-03-31
EP1041969A2 (en) 2000-10-11
NO20003246D0 (en) 2000-06-21
EP1041969B1 (en) 2003-03-26
AR014176A1 (en) 2001-02-07
AU747350B2 (en) 2002-05-16
CN1284861A (en) 2001-02-21
JP2001526208A (en) 2001-12-18
CA2316018A1 (en) 1999-07-01
IL136895A0 (en) 2001-06-14
US5968913A (en) 1999-10-19
WO1999032085A2 (en) 1999-07-01
DE69812708T2 (en) 2004-01-29
DE69812708D1 (en) 2003-04-30
KR20010033310A (en) 2001-04-25
ZA9811833B (en) 1999-07-20
ID26137A (en) 2000-11-23
BR9814426A (en) 2001-10-23

Similar Documents

Publication Publication Date Title
NO20003246L (en) New pharmaceutical preparations of uridine triphosphate
McDonald et al. Phagocyte uptake and transport of azithromycin
EP1562621B1 (en) Composition for treating ichthyosis using antitrypsin
Neu Microbiologic aspects of fluoroquinolones
JP2005508957A (en) Therapeutic compositions and uses
BRPI0719821B1 (en) stable composition in storage suitable for administration to patients
NO20026171L (en) Topical pharmaceutical formulations and methods of treatment
YU48099A (en) Composition that involves nutrient and herb and its application
US5756552A (en) Lyophilized pharmaceutical preparations capable of providing aqueous drug composition having property of reversible thermosetting gelation
CN1195524A (en) pharmaceutical preparations
ATE493981T1 (en) ONCE DAILY DOSAGE FORMS OF TROSPIUM
DK1044015T3 (en) Formulations with amylin agonist peptides and insulin
AU2024201523B2 (en) Intranasal epinephrine formulations and methods for the treatment of disease
ES2554167T3 (en) Methods and compositions useful in the treatment of mucositis
US20230069586A1 (en) Methods of using andrographolide, oridonin and isoliquiritigenin and derivatives thereof
WO2001047913A3 (en) Substituted n-benzyl-indol-3-yl glyoxylic acid derivatives having an anti-tumoral effect
WO1989003673A1 (en) Drug comprising the association of polymyxin b, tobramycin and amphotericin b administered by spraying
ATE350024T1 (en) LIQUID PREPARATION CONTAINING TOBRAMYCIN
FR2624015A1 (en) MEDICINE COMPRISING THE COMBINATION OF COLISTINE, TOBRAMYCIN AND AMPHOTERICIN B VAPORIZED
WO1989003672A1 (en) Drug comprising the association of polymyxin b, netilmycin and amphotericin b, administered by spraying
MXPA05005840A (en) Compounds that bind p2y2.
JP2007504268A5 (en)
Hutchison et al. A compilation of meropenem tissue distribution data
KR100405161B1 (en) Pharmaceutical composition for intramuscular injection containing loxoprofen
ES2427140T3 (en) Pharmaceutical lyophilized pharmaceutical preparation, stable, of recombinant polypeptides that fix carbohydrates

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application